Loading...

Brilliant Violet 421™ anti-human CD4 Antibody

Pricing & Availability
Clone
OKT4 (See other available formats)
Regulatory Status
RUO
Workshop
HCDM listed
Other Names
T4
Isotype
Mouse IgG2b, κ
Ave. Rating
Submit a Review
Product Citations
publications
OKT4_BV421_031512
Human peripheral blood lymphocytes were stained with CD4 (clone OKT4) Brilliant Violet 421™ (filled histogram) or mouse IgG2b Brilliant Violet 421™ isotype control (open histogram).
  • OKT4_BV421_031512
    Human peripheral blood lymphocytes were stained with CD4 (clone OKT4) Brilliant Violet 421™ (filled histogram) or mouse IgG2b Brilliant Violet 421™ isotype control (open histogram).
  • OKT4_BV421_CD4_Antibody_ICC_012021
    Human peripheral mononuclear cells were fixed with 2% paraformaldehyde (PFA) and then stained with 5 µg/ml CD4 (clone OKT4) Brilliant Violet 421™ (blue) and 5 µg/ml CD19 (clone HIB19) Alexa Fluor® 647 (red) for 30 minutes at room temperature. The image was captured by 40X objective.
Compare all formats See Brilliant Violet 421™ spectral data
Cat # Size Price Quantity Check Availability Save
317433 25 tests 132€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
317434 100 tests 296€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD4, also known as T4, is a 55 kD single-chain type I transmembrane glycoprotein expressed on most thymocytes, a subset of T cells, and monocytes/macrophages. CD4, a member of the Ig superfamily, recognizes antigens associated with MHC class II molecules and participates in cell-cell interactions, thymic differentiation, and signal transduction. CD4 acts as a primary receptor for HIV, binding to HIV gp120. CD4 has also been shown to interact with IL-16. 

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Human, Cynomolgus, Rhesus
Reported Reactivity
Chimpanzee
Antibody Type
Monoclonal
Host Species
Mouse
Immunogen
Human peripheral T cells
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation
The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 421™ under optimal conditions.
Concentration
Lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
ICC - Verified
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µL per million cells in 100 µL staining volume or 5 µL per 100 µL of whole blood.

Brilliant Violet 421™ excites at 405 nm and emits at 421 nm. The standard bandpass filter 450/50 nm is recommended for detection. Brilliant Violet 421™ is a trademark of Sirigen Group Ltd.


Learn more about Brilliant Violet™.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.
Excitation Laser
Violet Laser (405 nm)
Application Notes

The OKT4 antibody binds to the D3 domain of CD4 and does not block HIV binding. Additional reported applications (for the relevant formats) include: immunohistochemistry of frozen sections and blocking of T cell activation. This clone was tested in-house and does not work on formalin fixed paraffin-embedded (FFPE) tissue. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 317453 and 317454).

In a small subset of individuals, the OKT4 clone does not bind to CD4 due to polymorphisms in CD4.9

Application References
  1. Knapp W, et al. 1989. Leucocyte Typing IV. Oxford University Press. New York.
  2. Reinherz EL, et al. 1979. Proc. Natl. Acad. Sci. 76:4061.
  3. Kmieciak M, et al. 2009. J. Transl. Med. 7:89. (FC) PubMed
  4. Cicin-Sain L, et al. 2010. J. Immunol. 184:6739. PubMed
  5. Rosenzweig M, et al. 2001. J. Med. Primatol. 30:36.
  6. Linder J, et al. 1987. Am. J. Pathol. 127:1.
  7. Boche D, et al. 1999. J. Neurovirol. 5:232. (IHC)
  8. Reinherz EL, et al. 1979. Proc. Natl. Acad. Sci. USA. 76:4061. (Immunogen)
  9. Lederman S, et al. 1991. Mol Immunol. 28:1171-81.
Product Citations
  1. Bolton D, et al. 2016. J Virol. 90: 1321 - 1332. PubMed
  2. Bolton D, et al. 2017. PLoS Pathogens. 13(6):e1006445. PubMed
  3. Xu H, et al. 2019. Cell Stem Cell. 24:566. PubMed
  4. Saggau C, et al. 2022. Immunity. :. PubMed
  5. Hoang TN, et al. 2021. Cell. 184:460. PubMed
  6. Wilson PA, et al. 2021. PLoS One. 16:e0258316. PubMed
  7. Thaker YR, et al. 2022. Front Oncol. 12:884196. PubMed
  8. Bacher P, et al. 2020. Immunity. . PubMed
  9. Rodriguez-García A, et al. 2020. Mol Ther. 28:548. PubMed
  10. Bacher P et al. 2019. Cell. 176(6):1340-1355 . PubMed
  11. Leslie G, et al. 2016. PLoS Pathog. 12:e1005983. PubMed
  12. Liu Y, et al. 2018. JCI Insight. 3:. PubMed
  13. Martínez-Sabadell A, et al. 2022. STAR Protoc. 3:101712. PubMed
  14. García-Arriaza J, et al. 2015. J Virol. 89: 8525-8539. PubMed
  15. Etxeberria I, et al. 2020. Cancer Cell. 36(6):613-629. PubMed
  16. Li H, et al. 2019. Cell. 176:775. PubMed
  17. Cao W, et al. 2017. Immunity. 47:1182. PubMed
  18. Lisovsky I, et al. 2015. J Virol. 89: 9909 - 9919. PubMed
  19. Minagawa A, et al. 2018. Cell Stem Cell. 1.548611111. PubMed
  20. Hoang TN, et al. 2020. bioRxiv. . PubMed
  21. Cheng C, et al. 2020. Cell Reports. 32(5):107981. PubMed
  22. Di Genua C, et al. 2020. Cancer Cell. 37(5):690-704.e8.. PubMed
  23. Medvec AR, et al. 2018. Mol Ther Methods Clin Dev. 8:65. PubMed
  24. Weaver JD, et al. 2022. Oncoimmunology. 11:2141007. PubMed
  25. Kong R, et al. 2019. Cell. 178:567. PubMed
  26. Ryan E, et al. 2016. PLoS Pathog. 12: 1005412. PubMed
  27. Oh DY, et al. 2020. Cell. 181:1612. PubMed
  28. Ellis GI, et al. 2022. STAR Protoc. 3:101784. PubMed
  29. Marelli S, et al. 2020. Elife. :9. PubMed
  30. Evgin L, et al. 2020. Nat Commun. 2.671527778. PubMed
  31. Lickliter JD, et al. 2020. Drug Des Devel Ther. 14:1177. PubMed
  32. Dawson NA, et al. 2019. JCI Insight. 4:6. PubMed
  33. Naamati A, et al. 2019. Elife. 8:e41431. PubMed
  34. Georg P, et al. 2022. Cell. 185:493. PubMed
  35. Iwata A, et al. 2017. Nat Immunol. 18:563. PubMed
  36. Sehgal R, et al. 2022. Front Immunol. 13:828949. PubMed
  37. Harper J, et al. 2021. Nat Commun. 12:2866. PubMed
  38. Wang J, et al. 2020. Cell. 183(7):1867-1883.e26. PubMed
  39. Abdel-Mohsen M, et al. 2016. PLoS Pathog. 12: 1005677. PubMed
RRID
AB_11150413 (BioLegend Cat. No. 317433)
AB_2562134 (BioLegend Cat. No. 317434)

Antigen Details

Structure
Ig superfamily, type I transmembrane glycoprotein, 55 kD
Distribution

T cell subset, majority of thymocytes, monocytes/macrophages

Function
MHC class II co-receptor, lymphocyte adhesion, thymic differentiation, HIV receptor
Ligand/Receptor
MHC class II molecules, HIV gp120, IL-16
Cell Type
Macrophages, Monocytes, T cells, Thymocytes, Tregs
Biology Area
Immunology
Molecular Family
CD Molecules
Antigen References

1. Center D, et al. 1996. Immunol. Today 17:476.
2. Gaubin M, et al. 1996. Eur. J. Clin. Chem. Clin. Biochem. 34:723.

Gene ID
920 View all products for this Gene ID
UniProt
View information about CD4 on UniProt.org

Related FAQs

I am unable to see expression of T cell markers such as CD3 and CD4 post activation.
TCR-CD3 complexes on the T-lymphocyte surface are rapidly downregulated upon activation with peptide-MHC complex, superantigen or cross-linking with anti-TCR or anti-CD3 antibodies. PMA/Ionomycin treatment has been shown to downregulate surface CD4 expression. Receptor downregulation is a common biological phenomenon and so make sure that your stimulation treatment is not causing it in your sample type.
What is the F/P ratio range of our BV421™ format antibody reagents?

It is lot-specific. On average it ranges between 2-4.

Go To Top Version: 6    Revision Date: 01-20-2021

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account